冷冻消融治疗鼻炎:前瞻性多中心研究两年结果
该多中心前瞻性单臂研究评估后鼻神经冷冻消融治疗慢性鼻炎的长期安全性和有效性。结果显示鼻症状总分和生活质量持续显著改善,疗效维持至24个月。
要点
- 后鼻神经冷冻消融可显著改善慢性鼻炎症状,疗效维持24个月
- 超过80%的患者在所有随访点达到鼻症状总分的MCID
- 治疗相关严重不良事件少见,多数不良事件短暂且轻微
核心结论
- 冷冻消融治疗可显著且临床有意义地改善鼻炎症状和生活质量,疗效持续至治疗后24个月。
研究设计与样本
- 多中心、前瞻性、单臂临床研究,研究于2017年2月至2020年4月开展。
主要发现
- 鼻症状总分(rTNSS)在所有时间点较基线中位变化为-3.0或-4.0(P < .001)。
- 所有随访中超过80.0%的参与者达到rTNSS改善≥1点的最小临床重要差异(MCID)。
- 鼻结膜炎生活质量问卷(RQLQ)总分显示生活质量显著改善(P < .0001),超过77%的参与者达到RQLQ总分MCID(≥0.5分)。
- 临床总体印象改善(CGI-I)显示,除12个月访视(61.9%)外,所有访视中≥83.0%的参与者出现改善。
- 1例参与者发生2次治疗相关严重不良事件(鼻出血和填塞物滞留);23例参与者共报告29次非严重治疗相关不良事件,多数短暂且无需或仅需极少干预即可缓解。
临床怎么用
- 对于慢性鼻炎患者,后鼻神经冷冻消融可作为改善症状和生活质量的治疗选择,疗效可维持至24个月。
局限性
- 本研究为单臂设计,证据等级为4级。
- 长期随访样本量较小(57例完成24个月随访)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: To assess the long-term (12-24 months) safety and effectiveness of cryoablation of the posterior nasal nerve as treatment for chronic rhinitis. STUDY DESIGN: A multicenter, prospective, single-arm clinical study. METHODS: The study was conducted from February 2017 to April 2020. Study endpoints included change from baseline in the reflective Total Nasal Symptom Score (rTNSS), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), physician assessment of improvement using the Clinical Global Impression-Improvement (CGI-I), and the incidence of treatment-related adverse events. RESULTS: Ninety-one participants completed the study through the initial 12-month study period. Sixty-two participants consented to the long-term follow-up with 57 completing the 24-month follow-up. Significant improvements in the total rTNSS were reflected in a median change from baseline of -3.0 or -4.0 at all timepoints (P < .001). Greater than 80.0% of participants achieved the minimum clinically important difference (MCID) of improvement by ≥1 point on the rTNSS at all follow-ups. Total RQLQ scores indicated significant improvement (P < .0001) in quality of life. Over 77% of participants achieved the MCID (≥0.5 points) for the total RQLQ score. According to the CGI-I, ≥83.0% experienced improvement at all but the 12-month visit (61.9%). One participant experienced two treatment-related serious adverse events (epistaxis and retained pledget). A total of 29 nonserious treatment-related AEs were reported in 23 participants; most events were transient and resolved with little to no intervention. CONCLUSIONS: Cryotherapy significantly and clinically improves rhinitis symptoms and quality of life with outcomes that are durable through 24 months after treatment. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:1952-1957, 2021.
引用
- Ow RA, O'Malley EM, Han JK, et al. Cryosurgical Ablation for Treatment of Rhinitis: Two-Year Results of a Prospective Multicenter Study. Laryngoscope. 2021. PMID: 33616224. doi:10.1002/lary.29453
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。